

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The logo for EuroEyes, featuring the word "EuroEyes" in white sans-serif font on a dark blue rectangular background.

EuroEyes International Eye Clinic Limited
德視佳國際眼科有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1846)

VOLUNTARY ANNOUNCEMENT
FURTHER UPDATE ON IMPACT OF
THE CORONAVIRUS DISEASE 2019 (COVID-19)
OUTBREAK ON BUSINESS OPERATIONS

Reference is made to the announcement of EuroEyes International Eye Clinic Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) dated 15 March 2022 (the “**15 March Announcement**”) in relation to the impact of the COVID-19 outbreak on the Group’s business operations. Capitalised terms used herein shall have the same meanings as those defined in the 15 March Announcement unless the context requires otherwise.

BUSINESS AND OPERATIONS IN THE PEOPLE’S REPUBLIC OF CHINA (THE “PRC”)

As disclosed in the 15 March Announcement, there have been multiple waves of Omicron variant outbursts since the beginning of 2022 in some major cities where the Group operates its business, including Shanghai, Shenzhen, Beijing, and Hangzhou. Subsequent to it, Shanghai experienced two-month citywide static management, which caused the Group’s business in Shanghai to be suspended from the end of March 2022, and only resumed operation in early June 2022. Beijing imposed strict control measures, including intracity and intercity traffic restrictions and partial static management during May and June 2022, resulting in a negative impact on the number of out-patient consultation and surgery reservations in Beijing.

As of the date of this announcement, all of the Group’s clinics in the PRC have resumed normal operation. However, stringent public health measures are still undertaken, including mass testing for COVID-19, regional static management and especially intercity travel restrictions, resulting in travel inconvenience to patients from peripheral cities of the Group’s clinics, especially in Shanghai and Beijing, where there are plenty of patients coming from peripheral cities. These ongoing public health measures are expected to have a manageable impact on the Group’s business operations.

BUSINESS AND OPERATIONS IN EUROPE

After two years of pandemic restrictions, travel demand has roared back in Europe recently, given the restrictions are lifting. With the busy summer tourism season underway, a slight drop in the number of the Group’s eye surgery during a short period is observed in Germany and Denmark. However, the Directors expect that the fluctuation is temporary.

BUSINESS AND OPERATIONS OF THE GROUP

Based on the abovementioned impact of the COVID-19 outbreak on the Group and the information available to the Directors immediately preceding the publication of this announcement, the Board wishes to inform the shareholders and potential investors of the Company that during the six months ended 30 June 2022:

- (a) the total number of eye surgeries performed by the Group was 12,919, representing a slight decrease of approximately 2.5% (2021: 13,257 eye surgeries);
- (b) the number of refractive laser surgeries performed by the Group was 6,438, up approximately 2.3% from the corresponding period in 2021 (being 6,295 eye surgeries); and
- (c) the number of lens exchange surgeries was 5,146, which remained essentially flat compared with the corresponding period in 2021 (being 5,193 eye surgeries).

OPERATION RISK MANAGEMENT

Despite the global economic downturn, to the best knowledge of the Directors, there was no significant adverse impact on the business of the Group. The Group is prudent in its expansion plan, strives to improve its profitability, and maintains a healthy cash flow, which builds resilience under an unfavourable economic environment.

The Group has a far-reaching geographical coverage with operations in Germany, the PRC, Denmark and United Kingdom. The global footprints diversify the business risks generated from a single region, equipping the Group with a strong anti-risk ability and supporting the sustainable growth of the Group.

The Group will continue to regularly monitor the development of the COVID-19 pandemic and relevant public policies and assess its impact on the operations and financial performance. The Group will take appropriate measures as necessary and make further announcements as and when appropriate.

Shareholders and investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
EuroEyes International Eye Clinic Limited
Dr. Jørn Slot Jørgensen
Chairman and Executive Director

Hong Kong, 13 July 2022

As at the date of this announcement, the Board comprises Dr. Jørn Slot Jørgensen, Dr. Markus Braun, Dr. Ralf-Christian Lerche, Mr. Jannik Jonas Slot Jørgensen and Professor Dan Zoltan Reinstein as executive Directors; Mr. Marcus Huascar Bracklo as non-executive Director; Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive Directors.